Suppr超能文献

甲状腺乳头状癌弥漫性硬化变异型及滤泡癌岛状变异型的临床表现形式及演变

Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid.

作者信息

Albareda M, Puig-Domingo M, Wengrowicz S, Soldevila J, Matias-Guiu X, Caballero A, Chico A, De Leiva A

机构信息

Department of Endocrinology, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Spain.

出版信息

Thyroid. 1998 May;8(5):385-91. doi: 10.1089/thy.1998.8.385.

Abstract

We investigated whether the diffuse sclerosing variant of papillary carcinoma (diffuse sclerosing PC) and insular carcinoma (IC), two different subforms of differentiated carcinoma of the thyroid gland, have different clinical behaviors and prognosis in order to select appropriate therapy. The characteristics of clinical presentation, and outcome after therapy were evaluated in a series of 113 patients (18 males and 95 females) with differentiated thyroid carcinoma treated with the same protocol, of which 7 had diffuse sclerosing PC and 6 had IC; within this series, patients with diffuse sclerosing PC and IC were compared with 76 cases of papillary carcinoma (PC) and 24 cases of follicular carcinoma (FC), respectively. Diffuse sclerosing PC patients were younger (23+/-9 vs. 38+/-16 years) and had a higher degree of lymphatic metastases at diagnosis (100%) than patients with PC (47%). Five of 7 patients with diffuse sclerosing PC were alive and without evidence of disease compared to 34 of 76 patients with PC at follow-up (6.4+/-5.1 and 7.9+/-7 years, respectively). No prognostic differences were found between them. IC showed a more advanced stage of disease at diagnosis and a more aggressive clinical course with a higher percent of metastases and mortality than patients with FC at follow-up (1 patient died and 5 were alive with persistent disease at 4.8+/-3.7 years for IC; 22 were alive, 13 of them with persistent disease; and 2 died at 8.4+/-5.3 years for FC). We conclude that patients with diffuse sclerosing PC do not require a different treatment than that given to PC patients, while in contrast, IC cases need a more aggressive therapeutic approach.

摘要

我们研究了甲状腺乳头状癌的弥漫性硬化变体(弥漫性硬化性乳头状癌)和岛状癌这两种不同的分化型甲状腺癌亚型是否具有不同的临床行为和预后,以便选择合适的治疗方法。在113例接受相同治疗方案的分化型甲状腺癌患者(18例男性和95例女性)中评估了临床表现特征和治疗后的结局,其中7例为弥漫性硬化性乳头状癌,6例为岛状癌;在该系列中,分别将弥漫性硬化性乳头状癌和岛状癌患者与76例乳头状癌(PC)患者和24例滤泡状癌(FC)患者进行了比较。弥漫性硬化性乳头状癌患者比乳头状癌患者更年轻(23±9岁对38±16岁),且诊断时淋巴结转移程度更高(100%对47%)。随访时,7例弥漫性硬化性乳头状癌患者中有5例存活且无疾病证据,而76例乳头状癌患者中有34例存活(分别为6.4±5.1年和7.9±7年)。未发现它们之间存在预后差异。岛状癌在诊断时疾病分期更晚,临床过程更具侵袭性,转移率和死亡率高于随访时的滤泡状癌患者(岛状癌患者在4.8±3.7年时,1例死亡,5例存活且有持续性疾病;滤泡状癌患者22例存活,其中13例有持续性疾病;2例在8.4±5.3年时死亡)。我们得出结论,弥漫性硬化性乳头状癌患者不需要与乳头状癌患者不同的治疗,而相比之下,岛状癌病例需要更积极的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验